The opportunity The Unity Engine is used by millions of creators around the world to build powerful and engaging real-time experiences. At the heart of this is our flexible and powerful RT3D offering, giving users control
Stratford-upon-Avon, United Kingdom GBR-Brighton Montreal, Canada CAN-Montreal Copenhagen, Denmark GBR-London Full time JOBREQ- Lopportunité Le moteur Unity est utilisé par des millions de créateurs et créatrices à travers le monde pour concevoir des expériences en temps
# Global Knowledge Transfer Associate DirectorApplylocations: London (UK)time type: Full timeposted on: Posted Todayjob requisition id: R-22005 Title: Global Knowledge Transfer Associate Director Company: Ipsen Biopharm Ltd About Ipsen: Ipsen is a mid-sized global biopharmaceutical company
About Ipsen Ipsen is a mid-sized global biopharmaceutical company with a focus on transformative medicines in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Supported by nearly 100 years of development experience, with global hubs in
Title:Medical Science Liaison - NeuroscienceCompany:Ipsen LtdAbout Ipsen:Ipsen is a mid-sized global biopharmaceutical company with a focus on transformative medicines in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Supported by nearly 100 years of development experience,
Title:Global Knowledge Transfer Associate DirectorCompany:Ipsen Biopharm LtdAbout Ipsen:Ipsen is a mid-sized global biopharmaceutical company with a focus on transformative medicines in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Supported by nearly 100 years of development
Medical Science Liaison (UK) Field role based in the UK About the Company Pharmanovia is a dynamic, fast‑growing international pharmaceutical company with a portfolio of over 20 brands across more than 160 markets. Our mission is
Pharmanovia is a dynamic, fast-growing international pharmaceutical company with a portfolio of over 20 brands across more than 160 markets. Our mission is to improve patient health globally through the revitalisation of niche, tried-and-trusted medicines. Our